Updated Jul 16, 2026
MACKAY MARTIN has filed 2 SEC Form 4 filings across 2 companies in the last 90 days.
Martin Mackay is a corporate executive known for his role as a director at SpringWorks Therapeutics and Charles River Laboratories. He has experience in the biopharmaceutical industry but is not widely recognized in public forums.
| Role | Director |
|---|---|
| Notability | 20/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-05-11 | CRL | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. | A — Grant or award | 1.4K | $177.62 | $250K |
| 2026-05-11 | CRL | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. | A — Grant or award | 1.4K | $177.62 | $255K |
| 2025-07-01 | SWTX | SpringWorks Therapeutics, Inc. | D — Derivative transaction | 20.0K | — | |
| 2025-05-21 | CRL | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. | A — Grant or award | 815 | $134.98 | $110K |
| 2025-05-21 | CRL | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. | A — Grant or award | 946 | $134.98 | $128K |
Martin Mackay is a corporate executive known for his role as a director at SpringWorks Therapeutics and Charles River Laboratories. He has experience in the biopharmaceutical industry but is not widely recognized in public forums.…
2 primary Form 4 filings in the last 90 days, covering 2 companies.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live MACKAY MARTIN profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.